FY2025 · ended Dec 31, 2025 · Revenue $55.23M, -43.9% YoY · Filed Mar 13, 2026
Nektar Therapeutics (NKTR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $55.2 million and a net loss of $164.1 million. Free cash flow was -$208.7 million. As of Jun 30, 2026 it held $1.0 billion in cash and investments and $78.6 million in total debt.
Revenue (TTM)
$54.59M
-27.2% vs year-ago TTM
Net income (TTM)
$-157.13M
-28.5% vs year-ago TTM
Operating cash flow (TTM)
$-233.79M
-26.4% vs year-ago TTM
Free cash flow (TTM)
$-234.03M
-25.8% vs year-ago TTM
EPS (TTM)
$-6.49
+25.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
28.69M
-84.6% vs prior year
Net cash
$944.85M
as of Jun 30, 2026
Operating margin
-257.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NKTR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 906709
- Former names
- INHALE THERAPEUTIC SYSTEMS INC (until Jan 10, 2003); INHALE THERAPEUTIC SYSTEMS (until May 14, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M |
| Operating income | -$140.1M | -$105.2M | -$263.7M | -$376.2M | -$446.1M |
| Net income | -$164.1M | -$119.0M | -$276.1M | -$368.2M | -$523.8M |
| Diluted EPS | -$9.73 | -$8.68 | -$1.45 | -$1.97 | -$2.86 |
| Operating cash flow | -$208.5M | -$175.7M | -$192.6M | -$304.0M | -$412.7M |
| Free cash flow | -$208.7M | -$177.2M | -$193.5M | -$309.7M | -$427.6M |
| Total assets | $280.4M | $303.9M | $398.0M | $710.6M | $1.1B |
| Total liabilities | $190.6M | $243.1M | $267.0M | $344.0M | $437.7M |
| Stockholders' equity | $89.8M | $60.7M | $131.0M | $366.6M | $679.5M |
| Cash and investments | $245.8M | $269.1M | $329.4M | $505.0M | $798.8M |
| Total debt | $85.8M | $102.6M | $117.8M | $131.5M | $143.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Other events
|
Sep 25, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 5, 2026 |
All 1000 Nektar Therapeutics SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.